TLS Detect

RUO

Tertiary Lymphoid Structures

A research tool that uses AI to detect the presence or absence of TLS across tumor types from digital H&E slides
Request a demoCase Study

Clinical context

The potential of TLS in oncology research

Research shows TLS plays a crucial role in oncology by providing insights into the tumor's interaction with the immune system.*

Prognostic role
TLS are a major player in antitumor immune response and the presence of TLS has been associated with improved survival in several tumor types 1
Predictive biomarker
The assessment of TLS during drug development and clinical trials can serve as a predictive biomarker for response to certain immunotherapies
Therapeutic target
TLS can be assessed to help enhance the immune response and be a possible target for effective cancer immunotherapy 2
Combination therapies
TLS could guide the development of combination therapies that target both the tumor cells and the local immune environment
Trial optimization
TLS can support clinical trial optimization, to help better select trial participants to improve success rates across trial phases

Benefits of TLS detection

TLS presence is considered a novel biomarker to stratify the overall survival risk of untreated cancer patients and as a marker of efficient immunotherapy treatment.

A simple and standardized approach to measure TLS from routine digitised H&E slides could support the adoption of this biomarker as an independent predictor of response to immune checkpoint inhibitors (ICI).

With a sensitivity of 97%, TLS Detect has the potential to screen for TLS presence in tumors in a research setting.

TLS Detect

A pre-screening tool to determine the presence of TLS in a research setting

Testing tumor specimens
Pan-tumor

Suitable for tumor specimens across multiple indications

Digital pathology

Works with tumor tissue on digitized H&E slides

Intended users icon
Intended users

Researchers in a non-clinical routine setting

PDF report
PDF report

Delivered as PDF report with TLS status and H&E slide heatmap

97% sensitivity
Sensitivity**

Externally validated high sensitivity

Heatmap
Heatmap

Dynamic heatmap with TLS Detect score predictions

In a research setting

Determine the status of TLS

Sample

Tissue sample is taken and prepared as H&E slide

Digitization

H&E slide digitized

AI solution

TLS Detect extracts and analyzes features from the digitized slide

TLS Detect

PDF Report with dynamic heat map

Results

Results
‍
TLS

Presence of TLS, with analysis score provided

No TLS

No presence of TLS, with analysis score provided

"As a research tool, TLS Detect has the potential to pre-screen for TLS positive tumor samples, paving the way for optimization of research workflows in multiple tumor indications."
Antonie Italiano MD, PhD
Professor of Medicine & Head of Early Phase Trials Unit, Institut Bergonie, France
TLS Detect RUO was developed with annotated data from Comprehensive Cancer Center and a long-time partner of Owkin, Institut Bergonié.

Citations

  1. Vanhersecke et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nature Cancer Vol 2 794-802 (Aug 2021)
  2. Srivastava et al. IMpower110: Tertiary lymphoid structures and clinical outcomes in advanced non-small cell lung cancer treated with first-line atezolizumab or chemotherapy. Presented at The Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. (November 2023).
* Research tool only not to be used for diagnostic purposes
**97% sensitivity was achieved through validation on an external dataset (n=157 patients)
Manufacturer: Owkin France. Information updated on 23rd May 2024 - Version W003V1